Commentary

Role of the Fas/Fas ligand system in female reproductive organs: survival and apoptosis

Gil Mor[*], Shawn Straszewski, Marijke Kamsteeg

Department of Obstetrics and Gynecology, Yale University, School of Medicine, 333 Cedar St., FMB 202, New Haven, CT 06520-8063, USA

Abstract

For centuries, the question of ''whether there is life after death'' has intrigued the mind of philosophers and the same question fascinates researchers in the field of apoptosis today. The death of a cell is by no means the end of the story. On the contrary, growing evidence suggests that the clearance of apoptotic bodies by macrophages is an important regulatory component in tissue renewal. Without death by apoptosis, the life of reproductive tissues and their function would not be possible. The survival signals that counteract cell death also prepare the cells for apoptosis, and dead cells are important stimuli for tissue survival. The Fas/Fas ligand system is an important mediator of apoptosis and is an excellent example of this apparently contradictory phenomenon.
© 2002 Elsevier Science Inc. All rights reserved.

Keywords: Fas; Fas ligand; Estrogen; Macrophages; Apoptosis

1. Introduction

Apoptosis, or programmed cell death, is an active process essential for the development and homeostasis of all multi-cellular organisms [1]. Following cycles of proliferation and differentiation, unnecessary or potentially dangerous cells undergo apoptosis without affecting neighboring cells. As the primary mechanism of physiological cell loss, apoptosis plays an important role in the maintenance of normal tissue function throughout the body [2]. A delicate balance between the factors controlling cell proliferation and those controlling apoptosis properly maintains this tissue homeostasis. A disturbance in this balance may lead to either insufficient or excessive apoptosis, which then can contribute to a variety of pathological conditions including cancer, AIDS, and autoimmunity [2].

Due to the cyclic nature of the female reproductive system imposed by the episodic release of ovarian steroids, female reproductive organs such as the ovary, endometrium and mammary gland sustain continuous cycles of cell growth and apoptosis in response to hormonal changes,

and, therefore, are particularly dependent upon this means of cell death. These cycles of cell growth/death, also known as ''tissue remodeling'', play an important role not only in the normal physiology of the tissue, but also in the prevention of neoplastic transformation and cancer formation. Under the influence of survival factors such as estrogen, insulin or luteinizing hormone/follicle-stimulating hormone (LH/FSH), cells proliferate and increase in number (stage I). Subsequently, hormones such as progesterone or prolactin induce cell differentiation, which conveys two aspects: one to reduce the rate of cell proliferation and the other to commit differentiated cells to undergo apoptosis at the end of their function (stages II and III, respectively) [3]. However, this picture would be incomplete without mentioning a fourth stage, which is the removal of apoptotic cells (clearance) and its role in tissue homeostasis (Fig. 1).

In this review, we will discuss the interaction between sex hormones as survival factors, the Fas/FasL system, one of the main apoptotic pathways, and macrophages in tissue remodeling of the female reproductive organs and its implication in normal and patho-physiology.

2. Apoptosis

Apoptosis is a morphologically defined cell death and can be divided into three sections: initiation, execution, and

---

[*] Corresponding author. Tel.: +1-203-785-6294; fax: +1-203-785-4883.
E-mail address: gil.mor@yale.edu (G. Mor).

Abbreviations: DD, death domain; ER-α, estrogen receptor-α; ER-β, estrogen receptor-β; ERE, estrogen regulatory element; FADD, Fas-associated death domain; FasL, Fas ligand; FLIP, FLICE-like inhibitory protein; IAP, inhibitors of apoptosis; IFN-γ, interferon-γ; IL, interleukin; TNF, tumor necrosis factor.

Fig. 1. A complete view of tissue homeostasis. Our understanding of proliferation, differentiation, and cell death is incomplete without acknowledging the role of tissue clearance by macrophages.

termination. Unlike necrosis, which is generally caused by physical or chemical injury, apoptosis is normally triggered as a cellular response to survival factor deprivation. Moreover, necrosis results in the release of the cytoplasmic contents of the cell into the extracellular milieu followed by an inflammatory response, whereas apoptosis occurs without activation of the immune system. Apoptosis is typically characterized by membrane inversion, cell shrinkage, chromatin condensation and DNA degradation. In the terminal stages of apoptosis, the so-called apoptotic bodies that form during the execution phase are quickly engulfed by phagocytic cells such as macrophages [1], thereby preventing lysis and release of intracellular proteins, which otherwise may trigger autoimmune responses (see below).

Apoptosis can be initiated either by external factors including UV or γ-irradiation, chemotherapeutic drugs and death receptors, known as the "extrinsic pathway" [4,5], or by internal factors such as DNA damage or p53 activation through the "intrinsic pathway" [6]. In this latter pathway, the death signal is directed to the mitochondria and is regulated mainly by genes of the *bcl-2* superfamily (reviewed in Refs. [7,8]). The pro-apoptotic Bcl-2 family members such as Bax and Bak increase the permeability of the mitochondrial membrane to cytochrome *c* release. Consequently, a macromolecular complex called an apoptosome is formed, which activates caspase-9 with the help of apoptotic protease activating factor (APAF-1). In turn, caspase-9 activates caspase-3 and caspase-7, the point at which the two pathways converge.

If apoptosis is executed through the extrinsic pathway, the death signal is initiated by one of the members of the TNF receptor superfamily [9,10]. To transduce the apoptotic signal, TNF receptors have intracellular homophilic DDs, which mediate protein–protein interactions with other DD-containing adaptor proteins [11]. To date, six members of this family have been identified and include Fas (APO-1/CD95), TNF-R1, DR3, TRAIL-R1, TRAIL-R2 and DR6 [10,12]. Among the death receptors, Fas is the

most widely studied and best characterized [9,13]. Analogous to the other TNF family members, Fas is activated by its natural ligand, FasL, which exists in a soluble and membranal form [10].

3. Fas/FasL system

3.1. Structure and function

The pathway by which signaling through Fas leads to cell death (apoptosis) has been studied extensively [14]. It begins with the binding of FasL or an agonistic Fas monoclonal antibody (in experimental setups) to the extracellular region of the Fas receptor, resulting in its trimerization. Upon receptor oligomerization, the intracellular Fas-associated death domain (FADD) binds to the cytoplasmic tail of Fas via its death effector domain (DED) [11]. In turn, FADD recruits other cellular proteins through DDs to form the death-inducing signaling complex (DISC). Once the DISC is assembled, pro-caspase-8 or pro-caspase-10, the "initiator" cysteine proteases of the pathway, are able to bind to FADD. Analogous to other proteases, caspase-8 and caspase-10 normally exist in the cytoplasm in their non-active zymogen form until activated. According to the induced proximity model, high local concentrations of pro-caspase-8 and pro-caspase-10 are trans- or auto-catalytically cleaved once in close proximity to the DISC [15]. This is believed to occur by a two-step cleavage process that results in the formation of active caspase-8 or caspase-10 heterotetramers [16]. Following activation, caspase-8 or caspase-10 initiates the caspase cascade, which terminates with caspase-3 and caspase-7 cleavage. As effector caspases, caspase-3 and caspase-7 cleave a variety of substrates, including DNA repair enzymes and endonucleases such as inhibitor of caspase-activated deoxyribonuclease (ICAD). Consequently, caspase-activated deoxyribonuclease (CAD) is released from ICAD and enters the nucleus to non-specifically cut the genomic DNA into 200 bp fragments, eventually ending in apoptosis [17]. Altogether, this signaling through protein–protein interactions and proteolytic cleavage steps provides several points in the Fas-signaling pathway to modulate apoptosis (see Fig. 2).

3.2. Regulation

Since the machinery for Fas-mediated apoptosis is readily present within most cells, several mechanisms exist to keep cell death under control. Regulation of the Fas-mediated apoptotic machinery may occur at many steps along the recruitment-activation pathway. At the receptor level, Fas-mediated apoptosis can be blocked by either dominant negative decoy receptors, receptor endocytosis, or by soluble FasL (sFasL) [16]. Additionally, several intracellular inhibitors that block the Fas-signaling pathway have been characterized. As proximal inhibitors of the extrinsic

Fig. 2. Schematic representation of the intracellular components of the Fas/FasL pathway.

pathway, FLICE-like inhibiting proteins (FLIPs) are believed to compete with caspase-8 for binding to FADD, thereby preventing apoptotic signaling events downstream of caspase-8 activation [14]. The blocking of the Fas pathway also may occur at the effector stage (caspase-3 and -7 activation) by viral protein products such as cytokine response modifier A, p35, and IAP [18].

3.3. Signaling by Fas: the two-pathway model

What was originally thought to be a discrepancy between the data obtained from independent Bcl-2 over-expression studies and their effect on Fas led to the identification of two cell types termed Type I and Type II [19] (Fig. 2). Type I cells can undergo death receptor-mediated apoptosis without mitochondrial support (extrinsic pathway), whereas type II cells require the release of cytochrome *c* from mitochondria (intrinsic pathway) in order to translate the death signal. In contrast to type II cells, type I cells contain large amounts of DISC and caspase-8. As a consequence, type I cells can rely solely on the extrinsic pathway, whereas type II cells are depen-

dent upon both the extrinsic and intrinsic pathways to execute apoptosis. Thus, since Bcl-2 overexpression blocks only the intrinsic pathway, these observations may explain why certain cells are sensitive and others insensitive to Bcl-2 overexpression [20]. Besides cell lineage, the nature of the apoptotic stimulus and the microenvironment (e.g. cytokines and growth factors) are likely to play a role in whether apoptosis is executed by the extrinsic or intrinsic pathway [21].

4. Roles of the Fas/FasL system in tissue homeostasis

The Fas/FasL system was originally characterized in lymphocyte homeostasis, during which both immature and mature T cells are eliminated by a Fas-dependent mechanism termed activation-induced cell death (AICD) [22]. In particular, Fas and FasL have been implicated in the clonal deletion of self-reactive thymocytes in secondary lymphoid tissues, cytotoxic T cell killing and the removal of activated peripheral T cells following an immune response [23,24]. A loss-of-function mutation in the gene

encoding either Fas or FasL, as demonstrated in homozygous *lpr* (lymphoproliferation) and *gld* (generalized lymphoproliferation disease) mice, respectively, results in progressive lymphocyte accumulation and severe autoimmunity [25]. Details about the role of the Fas/FasL system in lymphocyte homeostasis have been reviewed extensively (see recent reviews by Krammer [14] and Sharma *et al.* [26]).

5. The Fas/FasL system in reproductive tissues

Reproductive organs such as the endometrium, mammary gland and ovary undergo cycles of cell proliferation and cell death as a result of changes in hormonal levels. During each cycle, there is a massive increase in cell number, which is then decreased by a coordinate process of cell death. New findings from our laboratory and others indicate the existence of a close interaction between sex hormones, mainly estrogen and progesterone, and the Fas/FasL system in the control and maintenance of tissue homeostasis. We will review work done in the endometrium, mammary gland and ovary.

5.1. Endometrium

The human endometrium, in preparation for pregnancy, undergoes cell growth in response to estrogen and progesterone. Recent studies have demonstrated the expression of Fas and FasL in human endometrium throughout the menstrual cycle. Using electron microscopy and immunohistochemistry, Yamashita and co-investigators [27] localized Fas and FasL to the Golgi apparatus and vesicles in the late proliferative phase. In addition, the same study revealed that both Fas and FasL are co-expressed in the plasma membrane of endometrial cells during the secretory phase of the menstrual cycle. This expression pattern suggests that the Fas/FasL system is involved in apoptosis of the human endometrium during menstruation and responds to hormonal changes.

Under the influence of estrogen, endometrial cells in the proliferative phase of the menstrual cycle are stimulated to divide and become resistant to apoptosis. Surprisingly, we found that estrogen increased FasL expression in endometrial cells, thymocytes and breast cancer cells [23,28,29]. It became clear that estrogen–estrogen receptor complexes directly regulate *FasL* gene expression through the presence of an estrogen regulatory element (ERE) in the *FasL* promoter, and mutations in the ERE region were shown to block the estrogenic effect completely [29,30]. Furthermore, the estrogenic effect on the *FasL* expression is not only dependent upon the ERE but also on the transcription factor AP-1 motif, also present in the *FasL* promoter [31]. Introduction of mutations in the AP-1 motif reduced the effect of estrogen by ∼60%. However, the effect of estrogen on *FasL* gene expression seems to depend upon the subtype of the estrogen receptor (ER-α or ER-β) present, since no reduction was observed in cells expressing ER-β alone (Fig. 3). This suggests that only ER-α is capable of activating AP-1. Furthermore, we demonstrated that estrogen induces cell proliferation in neuronal-like cells expressing ER-α, but induces apoptosis through the Fas/FasL system in those expressing ER-β, which correlates with the loss of ER-β in proliferative and malignant cells [32–34]. Since estrogen enhances proliferation and increases FasL expression, which seems contradictory, it is essential to note that an increase in FasL expression does not necessarily result in an increase in apoptosis because Fas needs to be expressed as well. Therefore, an increase in FasL expression by estrogen, while it induces cell proliferation, might serve to prepare the cell for apoptosis after proliferation and differentiation, thereby maintaining tissue homeostasis.

During the secretory phase, progesterone inhibits further proliferation and induces terminal differentiation. Through the process of differentiation, cells again become sensitive to apoptosis by the increase in expression of pro-apoptotic genes. While estrogen has a regulatory effect on FasL expression, it does not affect Fas expression [29]. Contrary to estrogen, progesterone regulates the expression of Fas, but not FasL. The induction of Fas by progesterone prepares


Fig. 3. Effect of estrogen on *FasL* promoter activity. The effect of estrogen on FasL activity was determined using a luciferase reporter gene system. Both ERE and AP-1 motifs are necessary for estrogen-induced FasL activation in ER-α bearing cells. On the other hand, only the ERE motif is necessary in ER-β bearing cells.

the cells to undergo apoptosis at the end of their function, which is determined by a decrease in hormonal levels, as is the case in the endometrium if implantation fails to occur [35]. Thus, circulating estrogen and progesterone levels decrease and the endometrium is shed during a process called menstruation. Until electron microscope studies confirmed the presence of apoptotic bodies in human endometrial cells during the late secretory phase of the cycle, menstruation was regarded as ischemic necrosis of the functional layer of the endometrium. Today, we have enough evidence showing that during involution of the endometrium, endometrial cells undergo rapid regression via apoptosis in preparation for the next menstrual cycle. Part of this process is mediated by the Fas/FasL system [35]. We demonstrated the role of Fas/FasL in endometrial cells by showing that withdrawal of estrogen and progesterone activates the Fas pathway and induces cell death in endometrial cells *in vitro*. Additionally, blocking the Fas pathway with a competitive FasL antibody prevented apoptosis following estrogen and progesterone withdrawal [35].

The effects of estrogen and progesterone on the expression of FasL and Fas, respectively, exemplify the delicate balance existing between cell survival and cell death and the role sex hormones play in the regulation of this important apoptotic pathway.

5.2. Mammary gland

The normal development of mammary glands during pregnancy is characterized by a period of epithelial cell proliferation followed by the differentiation of milk-producing cells after parturition [36]. Walker and co-workers have demonstrated that in the mouse and rat, mammary tissue involution is accompanied by the cleavage of chromatin into oligonucleotide fragments [37], a characteristic of apoptosis [1,38,39]. These and other studies [40,41] provide strong evidence that cell loss during involution occurs by programmed cell death. The occurrence of such remodeling is supported by experimental manipulations, which have shown that after litter removal, lactation can be maintained and involution impeded by the injection of lactant hormones [42,43].

In a recent study, we demonstrated that although Fas protein is present during normal breast development, it is absent during pregnancy and lactation, only to return after weaning. On the other hand, FasL is present during pregnancy, lactation and weaning, but not in the virgin mouse. The overlapping expression of Fas and FasL during involution is accompanied by apoptosis of the mammary epithelium [3].

We further evaluated the role of Fas and FasL in mammary gland remodeling using Fas-deficient MRL/*lpr* mice, in which the *Fas* gene is interrupted by an early transposable element and carries a point mutation in the DD, and the C3H/*gld* mice, which have non-functional FasL [44,45]. Lack of Fas or functional FasL in the MRL/*lpr* and C3H/*gld*

mice, respectively, prevented apoptosis of mammary cells during the first 3 days of involution. However, apoptotic cells were found at day 4 of involution, suggesting that the Fas/FasL system may play an important role in the early stage of involution. The timing of the differences in mammary apoptotic cells in the MRL/*lpr* and C3H/*gld* mice is crucial in light of the two-stage model of involution proposed by Lund and co-workers [46]. The authors proposed that post-lactational involution of the mammary gland is characterized by two distinct phases. The first phase of involution is characterized by rapid induction of pro-apoptotic genes within the epithelium (days 1–4) [46,47]. This is the period when Fas and FasL are active, based on the absence of apoptotic cells in the mammary glands of MRL/*lpr* and C3H/*gld* mice. The second phase of involution is characterized by the induction of genes encoding proteases within stroma cells that result in the remodeling of the gland [46]. This phase is Fas/FasL-independent as shown by the presence of apoptotic cells in the mammary glands of MRL/*lpr* and C3H/*gld* mice. This chronology is consistent with Fas and FasL being expressed on the cell surface during the first phase, resulting in the ''suicide'' of the secretory epithelium. Cells escaping the first phase are then removed by a secondary mechanism that is Fas-independent. At this time, stroma cells, including macrophages may induce cell death of the epithelium to ensure the removal of secretory cells [48].

The expression of Fas and FasL in the involuting mammary gland is not homogeneous, even in the same gland or duct. Using immunohistochemistry, we found that some cells were positively stained, while other nearby cells were negative, suggesting differences in the remodeling stages between cellular compartments of the glands and ducts. Moreover, this heterogeneity of apoptosis provides a survival advantage since the entire function of the gland is not lost immediately when suckling stops. Rather, apoptotic factors (e.g. Fas/FasL) trigger graded programmed cell death and decreased milk production, allowing for suckling to be restarted if necessary. If pups resume suckling, the hormonal microenvironment, which constitutes a survival factor, inhibits apoptosis and promotes restoration of milk production. However, if suckling is not restored, the second phase of involution takes place, promoting disruption of the basement membrane and extracellular matrix, resulting in a complete remodeling of the gland to a state resembling the mature virgin [3,47].

5.3. Ovary

Two major stages of oocyte degeneration can be distinguished in the ovary: germ cell attrition, which occurs mainly prenatally and follicle atresia, a process during reproductive life (reviewed in Ref. [49]). At 24 weeks of gestation, the number of oocytes in the human ovaries reaches a maximum of 7 million. At birth, about 0.7 to 2 million oocytes remain in the ovaries and at puberty only

400,000 are left. Additionally, during every estrous cycle, about 5–12 follicles resume development and usually only one follicle becomes dominant and is ovulated, whereas the other follicles degenerate. Ovarian follicular degeneration or atresia is a hormonally controlled apoptotic process of the granulosa cells and to some extent the theca cells, which eliminates subordinate follicles [50]. Ovulation results in damage of the ovarian surface epithelium, which will be repaired by subsequent proliferation and apoptosis. After ovulation, the corpus luteum (CL) develops, which regresses after a few days in the case of non-pregnancy, or after a few months when successful pregnancy occurs. Several experiments suggest that there is an important role for the Fas pathway in follicular atresia, ovarian surface epithelium repair and luteolysis.

The expression of Fas and FasL in mammalian ovaries varies between different cell types and throughout the menstrual cycle. Studies on mouse ovaries revealed that granulosa cells of large follicles and some medium follicles express Fas, whereas no Fas expression was detected in granulosa cells of small follicles and in oocytes [51]. When we evaluated Fas and FasL expression in the female rat, FasL was highly expressed in estrous, decreased during metestrous and diestrous and not detected in proestrous, while Fas protein expression increased during proestrous and estrous and decreased during metestrous and diestrous [33]. In cows, Fas and FasL are expressed in granulosa and theca cells of day 5 and 11 follicles; however, the Fas mRNA level is higher in granulosa cells and the FasL mRNA level is higher in theca cells [52]. At day 5 of the estrous cycle, granulosa and theca cells of subordinate atretic follicles have higher Fas and FasL mRNA content than healthy dominant follicles, which correlates with increased sensitivity to FasL-induced apoptosis in granulosa, but not theca cells [52,53]. During the transition of healthy dominant bovine follicles (day 5) into atretic dominant follicles (day 11), the level of Fas mRNA increases in theca cells, whereas the FasL mRNA level increases in granulosa cells [53]. Similarly, in human ovaries, Fas was localized to granulosa and theca cells of atretic, but not healthy antral follicles [54,55]. Therefore, it is likely that the Fas pathway is involved in the regression of subordinate follicles and follicle atresia.

Several studies also suggest that apoptosis during the regression of the CL may be mediated by the Fas pathway. In mice, luteal cells of regressing CL have a marked increase in Fas expression compared to that of non-regressing CL [51]. Other evidence comes from studies performed on rat CL, where Fas and FasL were found in the cytoplasm of luteal cells, but not in endothelial cells [56]. When immunocytochemistry was performed on rat CL, Fas was detected only at day 1 of pregnancy and postpartum during luteolysis. Additionally, although FasL mRNA was present throughout pregnancy and postpartum, an increase in Fas protein was found only during luteolysis [56].

In vivo experiments strengthened the *in vitro* experiments described above: intraperitoneal injection of an agonistic Fas antibody (RK-8) into mice resulted in the presence of more pycnotic bodies in granulosa cells of the follicles and a decrease in the number of ovulated ova and corpora lutea [51]. Additionally, 20-week-old *lpr* and *gld* mutant mice, which have an extremely reduced Fas expression or encode non-functional FasL protein, respectively, showed an increase in the number of medium follicles [51].

5.4. Role of gonadotrophic hormones in Fas-mediated apoptosis

Ovarian cells are hormone sensitive and respond to hormonal changes either by proliferating or dying. Numerous studies suggest a role of gonadotrophins in ovarian homeostasis. For example, gonadotrophin decreased the amount of apoptosis in rat granulosa cells and in primary cultures of human granulosa cells, which correlated with a decreased expression of both Fas and FasL [57,58].

In cycling rats, the prolactin surge during the proestrous afternoon induces apoptosis in luteal cells and correlates with an increase in FasL expression [59]. In another set of experiments, FasL mRNA was specifically found in CD3-positive luteal immunocytes, whereas Fas mRNA was only detected in the luteal steroidogenic cells [60]. Separation of the non-steroidogenic from the steroidogenic cells *in vitro* abolished prolactin-induced apoptosis, showing that the FasL-expressing immune cells are required for the prolactin-induced apoptosis of the steroidogenic cells [60]. However, during pregnancy, prolactin did not induce apoptosis in luteal steroidogenic cells, which was due to the action of progesterone [61]. Progesterone turned out to reduce the amount of Fas mRNA in the CL, thereby suppressing the sensitivity of luteal steroidogenic cells to prolactin-induced apoptosis.

6. Macrophages, clearance, and the Fas/FasL system

Macrophages are not merely scavengers of apoptotic cells; they are crucial both for the clearance of apoptotic cells generated by tissue remodeling or injury, and for host defense against bacteria or protozoa. Where ingestion of bacteria triggers macrophages to secrete molecular mediators capable of inducing a protective, but potentially injurious inflammatory response [62], ingestion of apoptotic cells elicits the production of anti-inflammatory cytokines [63]. It was shown that the production of Th2-type cytokines by macrophages helps to create an anti-inflammatory microenvironment, which facilitates cell survival and proliferation, prevents tissue damage and induces immune tolerance [63].

Additionally, the lack of an inflammatory response during apoptosis has also been attributed to the rapid phagocytosis of apoptotic cells before lysis, thereby pre-

venting the release of noxious contents that provoke inflammation and tissue damage [63]. Survival factors such as estrogen increase the phagocytic capacity of macrophages and, therefore, contribute to tissue survival [64].

During the first few weeks of human implantation, a high number of macrophages is found in the maternal decidua and in tissues proximal to the placenta [65]. Similarly, macrophages accumulate at or near the implantation site in rodents [66]. Hunt [67] proposed that maternal macrophages assist in the tissue remodeling necessary to accommodate expansion of extraembryonic tissue. Macrophages eliminate apoptotic uterine epithelial cells surrounding the blastocyst, during which an anti-inflammatory environment may be formed by increased anti-inflammatory cytokines [30] (Fig. 4).

The anti-inflammatory action of apoptotic cell phagocytosis may be perturbed in certain diseases ([30] and Fig. 5).

For example, in the anti-phospholipid syndrome, phospholipid antibodies in apoptotic cells bind to the Fc receptors in macrophages, resulting in secretion of TNF-α, a Th-1 type, pro-inflammatory cytokine [68]. If this occurs during pregnancy, cytokine production by macrophages and other cells at the maternal–fetal interface may be altered drastically [69]. Our studies with trophoblast cells are in concert with this concept because they indicate that enhanced levels of pro-inflammatory macrophage products increase Fas expression and enhance trophoblast sensitivity to Fas-mediated apoptosis [30]. Two recent studies have described an increase in trophoblast cell apoptosis in pregnancies complicated by preeclampsia [70,71]. Interestingly, high levels of neutrophil activation have also been described in preeclamptic patients [72–74]. It is possible that a dense neutrophil infiltration may alter the surrounding environment at the maternal–fetal interface, thereby promoting the up-regulation of Fas expression in non-immune cells such as


Fig. 4. Immune privilege. (Top panel) Trophoblast cells induce apoptosis of activated immune cells through the expression of FasL on its surface. FasL expression is supported by locally produced anti-inflammatory cytokines. (Bottom panel) Bacterial infection or excessive apoptosis activates macrophages towards a pro-inflammatory cytokine profile. The inflammatory response further induces cell apoptosis and tissue damage.

Fig. 5. Model of tissue remodeling, normal and cancer.

trophoblasts and vascular endothelium and allowing FasL-induced inflammation and apoptosis [75].

7. Fas and FasL expression and function in gynecological cancers

Since Fas and FasL are expressed in reproductive tissues and, as discussed above, have an important role in tissue remodeling, aberrant alterations in Fas or FasL expression may lead to abnormalities. Both Fas and FasL proteins are found in ovarian cancer tissue and primary ovarian cancer cultures [76,77]. Similarly, FasL expression was found in breast cancer cells [78,79], and its level of expression has been shown to correlate with low prognostic value and decreased survival [80].

In ovarian carcinoma tissue, Fas mRNA levels, but not FasL mRNA levels, are decreased compared to normal ovarian tissue [81]. Similarly, Mottolese and co-investigators [82] demonstrated that breast cancer patients with Fas-positive tumors exhibited longer disease-free survival than those having Fas-negative tumors.

Despite the presence of Fas and FasL, ovarian and breast cancer cells are resistant to Fas-mediated apoptosis [76,83].

8. Role of FasL in immune privilege: the good and the bad

The Fas/FasL system is involved in the establishment and maintenance of immune-privileged sites such as the eye, brain [84], testis and trophoblast [85,86]. Immune privilege refers to organs or tissues that prohibit the spread

of inflammation in response to an antigen in order to avoid the destruction of nearby tissue. Recent studies revealed that FasL expression in the eye limits inflammation by removing Fas-bearing immune cells that infiltrate the blood–ocular barrier. Similarly, in addition to the classical blood–brain barrier, we described the existence of an immune brain barrier (IBB), which represents an active system regulating the movement of immune cells to and from the central nervous system. This IBB is generated by the expression of FasL on neurons and microglia cells in the neuropil and on astrocytes around blood vessels, functioning as an active and selective barrier to activated immune cells [84].

Tumors are also established as immune privileged sites since neoplastic cells are able to escape immune surveillance and avoid an inflammatory response. We and others have demonstrated that the expression of FasL in cancer cells may represent a mechanism by which neoplastic cells escape immune surveillance (see Fig. 4) [79,87–89]. Cancer cells express FasL, which interacts with and activates the Fas receptor present on the surface of immune cells that infiltrate the tumor [79]. Furthermore, FasL expression on neoplastic cells is enhanced by cytokines and hormones produced by the immune infiltrate present in the vicinity of the tumor [90]. Besides reducing the number of circulating cytotoxic T cells, the expression of FasL on tumor cells can also abolish the production of antibodies and limit immunological memory against the tumor during a process called tumor counterattack [79,87].

In summary, it can be concluded that the Fas/FasL system mediates tissue remodeling and protects against the accumulation of malignant cells (the good effect); however, if the Fas pathway is blocked and the cell becomes resistant to

Fas-mediated apoptosis, FasL in the malignant cell will induce apoptosis in the immune cells (the bad effect).

9. The model

We can summarize the above-discussed studies in the following model using the mammary gland as an example of reproductive tissue (see Fig. 5). Apoptosis of proliferating cells is prevented through the inhibition of Fas expression. Changes in the mammary gland microenvironment, such as hormonal withdrawal (e.g. post-lactation) will deprive the cells of their support/survival stimuli, thereby allowing the activation of the apoptotic machinery through the Fas receptor. Tumor suppressor genes such as *p53* and c-*myc* induce Fas expression and/or its translocation to the cell surface, where it meets its ligand and induces apoptosis. This process allows both normal tissue remodeling and removal of mutated cells (Fig. 5: Normal). However, a decrease in Fas expression/activation may lead to proliferation of transformed cells. Furthermore, FasL expression on neoplastic cells is enhanced by cytokines and hormones produced by the immune infiltrate present in the vicinity of the tumor. Cancer cells with an increased FasL expression might send apoptotic signals to the wrong cells such as immune cells and escape immune surveillance. Thus, an immune privileged site is created similar to those natural sites such as the eye, testis and brain (Fig. 5: Cancer).

Acknowledgments

References

[1] Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239–57.

[2] Wyllie AH, Kerr JF, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol 1980;68:251–306.

[3] Song J, Sapi E, Brown W, Nilsen J, Tartaro K, Kacinski B, Naftolin F, Mor G. Expression of Fas and Fas ligand during pregnancy, lactation and involution and its potential role during mammary gland remodeling. J Clin Invest 2000;106:1209–24.

[4] Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 1999;15:269–90.

[5] McGahon AJ, Martin SJ, Bissonnette RP, Mahboubi A, Shi Y, Mogil RJ, Nishioka WK, Green DR. The end of the (cell) line: methods for the study of apoptosis *in vitro*. Methods Cell Biol 1995;46:53–85.

[6] Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770–6.

[7] Rich T, Allen RL, Wyllie AH. Defying death after DNA damage. Nature 2000;407:777–83.

[8] Rich T, Watson CJ, Wyllie A. Apoptosis: the germs of death. Nat Cell Biol 1999;1:E69–71.

[9] Nagata S, Golstein P. The Fas death factor. Science 1995;267:1449–56.

[10] Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 1999;17:331–67.

[11] Stegh AH, Schickling O, Ehret A, Scaffidi C, Peterhansel C, Hofmann TG, Grummt I, Krammer PH, Peter ME. DEDD, a novel death effector domain-containing protein, targeted to the nucleolus. EMBO J 1998;17:5974–86.

[12] Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S, Peter ME. Apoptosis signaling by death receptors. Eur J Biochem 1998;254:439–59.

[13] Schmitz I, Walczak H, Krammer PH, Peter ME. Differences between CD95 type I and II cells detected with the CD95 ligand. Cell Death Differ 1999;6:821–2.

[14] Krammer PH. CD95's deadly mission in the immune system. Nature 2000;407:789–95.

[15] Muzio M, Salvesen GS, Dixit VM. FLICE induced apoptosis in a cell-free system. Cleavage of caspase zymogens. J Biol Chem 1997;272:2952–6.

[16] Scaffidi C, Kischkel FC, Krammer PH, Peter ME. Analysis of the CD95 (APO-1/Fas) death-inducing signaling complex by high-resolution two-dimensional gel electrophoresis. Methods Enzymol 2000;322:363–73.

[17] Scaffidi C, Kirchhoff S, Krammer PH, Peter ME. Apoptosis signaling in lymphocytes. Curr Opin Immunol 1999;11:277–85.

[18] Brunner T, Mogil RJ, LaFace D, Yoo NJ, Mahboubi A, Echeverri F, Martin SJ, Force WR, Lynch DH, Ware CF, Green DR. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 1995;373:441–4.

[19] Scaffidi C, Schmitz I, Zha J, Korsmeyer SJ, Krammer PH, Peter ME. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J Biol Chem 1999;274:22532–8.

[20] Scaffidi C, Krammer PH, Peter ME. Isolation and analysis of components of CD95 (APO-1/Fas) death-inducing signaling complex. Methods 1999;17:287–91.

[21] Villunger A, Ghaffari-Tabrizi N, Tinhofer I, Krumböck N, Bauer B, Schneider T, Kasibhatla S, Greil R, Baier-Bitterlich G, Überall F, Green DR, Baier G. Synergistic action of protein kinase C θ and calcineurin is sufficient for Fas ligand expression and induction of a crmA-sensitive apoptosis pathway in Jurkat T cells. Eur J Immunol 1999;29:3549–61.

[22] Van Parijs L, Peterson DA, Abbas AK. The Fas/Fas ligand pathway and Bcl-2 regulate T cell responses to model self and foreign antigens. Immunity 1998;8:265–74.

[23] Mor G, Munoz A, Redlinger Jr R, Silva I, Song J, Lim C, Kohen F. The role of the Fas/Fas ligand system in estrogen-induced thymic alteration. Am J Reprod Immunol 2001;46:298–307.

[24] Nagata S. Fas and Fas ligand: a death factor and its receptor. Adv Immunol 1994;57:129–35.

[25] Takahashi T, Tanaka M, Brannan C, Jenkins N, Copeland N, Suda T, Nagata S. Generalized lymphoproliferative disease in mice, caused by point mutation in the Fas ligand. Cell 1994;76:969–76.

[26] Sharma K, Wang RX, Zhang LY, Yin DL, Luo XY, Solomon JC, Jiang RF, Markos K, Davidson W, Scott DW, Shi YF. Death the Fas way: regulation and pathophysiology of CD95 and its ligand. Pharmacol Ther 2000;88:333–47.

[27] Yamashita H, Otsuki Y, Matsumoto K, Ueki K, Ueki M. Fas ligand, Fas antigen and Bcl-2 expression in human endometrium during the menstrual cycle. Mol Hum Reprod 1999;5:358–64.

[28] Song RXD, Mor G, Naftolin F, McPherson RA, Song J, Zhang Z, Yue W, Wang J, Santen RJ. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17β-estradiol. J Natl Cancer Inst 2001;93:1714–23.

[29] Mor G, Kohen F, Garcia-Velasco J, Nilsen J, Brown W, Song J, Naftolin F. Regulation of Fas ligand expression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen. J Steroid Biochem Mol Biol 2000;73:185–94.

[30] Aschkenazi S, Straszewski S, Verwer KM, Foellmer H, Rutherford T, Mor G. Differential regulation and function of the Fas/Fas ligand system in human trophoblast cells. Biol Reprod 2002;66:1853–61.

[31] Matsui K, Omura S, Cui H, Schauer SL, Sonenshein GE, Ju S-T. Proteasome regulation of Fas ligand cytotoxicity. Eur J Immunol 1997;27:2269–78.

[32] Nilsen J, Mor G, Naftolin F. Estrogen-regulated developmental neuronal apoptosis is determined by estrogen receptor subtype and the Fas/Fas ligand system. J Neurobiol 2000;43:64–78.

[33] Sapi E, Brown W, Aschkenazi S, Tartaro K, Lim C, Munoz A, Kacinski B, Rutherford T, Mor G. Regulation of Fas ligand expression by estrogen in normal ovary. J Soc Gynecol Invest 2002;9:243–50.

[34] Rutherford T, Brown W, Sapi E, Aschkenazi S, Munoz A, Mor G. Absence of estrogen receptor β expression in metastatic ovarian cancer. J Obstet Gynecol 2000;96:417–21.

[35] Song J, Rutherford T, Naftolin F, Brown S, Mor G. Hormonal regulation of apoptosis and the Fas and Fas ligand system in human endometrial cells. Mol Hum Reprod 2002;8:447–55.

[36] Russo J, Tay LK, Russo IH. Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat 1982;2:5–73.

[37] Walker NI, Bennett RE, Kerr JF. Cell death by apoptosis during involution of the lactating breast in mice and rats. Am J Anat 1989;185:19–32.

[38] Morris RG, Hargreaves AD, Duvall E, Wyllie AH. Hormone-induced cell death. 2. Surface changes in thymocytes undergoing apoptosis. Am J Pathol 1984;115:426–36.

[39] Duvall E, Wyllie AH, Morris RG. Macrophage recognition of cells undergoing programmed cell death (apoptosis). Immunology 1985;56:351–8.

[40] Quarrie LH, Addey CV, Wilde CJ. Apoptosis in lactating and involuting mouse mammary tissue demonstrated by nick-end DNA labelling. Cell Tissue Res 1995;281:413–9.

[41] Quarrie LH, Addey CV, Wilde CJ. Programmed cell death during mammary tissue involution induced by weaning, litter removal, and milk stasis. J Cell Physiol 1996;168:559–69.

[42] Ossowski L, Biegel D, Reich E. Mammary plasminogen activator: correlation with involution, hormonal modulation and comparison between normal and neoplastic tissue. Cell 1979;16:929–40.

[43] Strange R, Friis RR, Bemis LT, Geske FJ. Programmed cell death during mammary gland involution. Methods Cell Biol 1995;46:355–68.

[44] Adachi M, Suematsu S, Kondo T, Ogasawara J, Tanaka T, Yoshida N, Nagata S. Targeted mutation in the *Fas* gene causes hyperplasia in peripheral lymphoid organs and liver. Nat Genet 1995;11:294–300.

[45] Adachi M, Watanabe-Fukunaga R, Nagata S. Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of *lpr* mice. Proc Natl Acad Sci USA 1993;90:1756–60.

[46] Lund LR, Romer J, Thomasset N, Solberg H, Pyke C, Bissell MJ, Dano K, Werb Z. Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways. Development 1996;122:181–93.

[47] Li M, Liu X, Robinson G, Bar-Peled U, Wagner KU, Young WS, Hennighausen L, Furth PA. Mammary-derived signals activate programmed cell death during the first stage of mammary gland involution. Proc Natl Acad Sci USA 1997;94:3425–30.

[48] Furth PA. Introduction: mammary gland involution and apoptosis of mammary epithelial cells. J Mammary Gland Biol Neoplasia 1999;4:123–7.

[49] Kaipia A, Hsueh AJ. Regulation of ovarian follicle atresia. Annu Rev Physiol 1997;59:349–63.

[50] Hughes Jr FM, Gorospe WC. Biochemical identification of apoptosis (programmed cell death) in granulosa cells: evidence for a potential mechanism underlying follicular atresia. Endocrinology 1991;129:2415–22.

[51] Sakamaki K, Yoshida H, Nishimura Y, Nishikawa S, Manabe N, Yonehara S. Involvement of Fas antigen in ovarian follicular atresia and luteolysis. Mol Reprod Dev 1997;47:11–8.

[52] Porter DA, Vickers SL, Cowan RG, Huber SC, Quirk SM. Expression and function of Fas antigen vary in bovine granulosa and theca cells during ovarian follicular development and atresia. Biol Reprod 2000;62:62–6.

[53] Porter DA, Harman RM, Cowan RG, Quirk SM. Relationship of Fas ligand expression and atresia during bovine follicle development. Reproduction 2001;121:561–6.

[54] Kondo H, Maruo T, Peng X, Mochizuki M. Immunological evidence for the expression of the Fas antigen in the infant and adult human ovary during follicular regression and atresia. J Clin Endocrinol Metab 1996;81:2702–10.

[55] Maruo T, Laoag-Fernandez JB, Takekida S, Peng X, Deguchi J, Samoto T, Kondo H, Matsuo H. Regulation of granulosa cell proliferation and apoptosis during follicular development. Gynecol Endocrinol 1999;13:410–9.

[56] Roughton SA, Lareu RR, Bittles AH, Dharmarajan AM. Fas and Fas ligand messenger ribonucleic acid and protein expression in the rat corpus luteum during apoptosis-mediated luteolysis. Biol Reprod 1999;60:797–804.

[57] Kim JM, Yoon YD, Tsang BK. Involvement of the Fas/Fas ligand system in p53-mediated granulosa cell apoptosis during follicular development and atresia. Endocrinology 1999;140:2307–17.

[58] Asselin E, Xiao CW, Wang YF, Tsang BK. Mammalian follicular development and atresia: role of apoptosis. Biol Signals Recept 2000;9:87–95.

[59] Kuranaga E, Kanuka H, Bannai M, Suzuki M, Nishihara M, Takahashi M. Fas/Fas ligand system in prolactin-induced apoptosis in rat corpus luteum: possible role of luteal immune cells. Biochem Biophys Res Commun 1999;260:167–73.

[60] Kuranaga E, Kanuka H, Furuhata Y, Yonezawa T, Suzuki M, Nishihara M, Takahashi M. Requirement of the Fas ligand-expressing luteal immune cells for regression of corpus luteum. FEBS Lett 2000;472:137–42.

[61] Kuranaga E, Kanuka H, Hirabayashi K, Suzuki M, Nishihara M, Takahashi M. Progesterone is a cell death suppressor that downregulates Fas expression in rat corpus luteum. FEBS Lett 2000;466:279–82.

[62] Medzhitov R, Janeway Jr C. Innate immunity. New Engl J Med 2000;343:338–44.

[63] Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature 1997;390:350–1.

[64] Schreiber A, Nettl F, Sanders M, King M, Szabolcs P, Friedman D, Gomez F. Effect of endogenous and synthetic sex steroids on the clearance of antibody-coated cells. J Immunol 1988;141:2959–66.

[65] Miller L, Hunt J. Sex steroid hormones and macrophage function. Life Sci 1996;59:1–14.

[66] Tachi C, Tachi S. Role of macrophages in the maternal recognition of pregnancy. J Reprod Fertil Suppl 1989;37:63–8.

[67] Hunt J. Cytokine networks in the uteroplacental unit: macrophages as pivotal regulatory cells. J Reprod Immunol 1989;16:1–17.

[68] Manfredi AA, Rovere P, Galati G, Heltai S, Bozzolo E, Soldini L, Davoust J, Balestrieri G, Tincani A, Sabbadini MG. Apoptotic cell clearance in systemic lupus erythematosus. I. Opsonization by antiphospholipid antibodies. Arthritis Rheum 1998;41:205–14.

[69] Guleria I, Pollard JW. The trophoblast is a component of the innate immune system during pregnancy. Nat Med 2000;6:589–93.

[70] Fisher D. Apoptosis in cancer therapy. Cell 1994;78:539–42.

[71] Allaire A, Ballenger K, Wells S, McMahon M, Lessey B. Placental apoptosis in preeclampsia. Obstet Gynecol 2000;96:271–6.

[72] Clark P, Boswell F, Greer IA. The neutrophil and preeclampsia. Semin Reprod Endocrinol 1998;16:57–64.

[73] Greer IA, Dawes J, Johnston TA, Calder AA. Neutrophil activation is confined to the maternal circulation in pregnancy-induced hypertension. Obstet Gynecol 1991;78:28–32.

[74] Greer IA, Haddad NG, Dawes J, Johnstone FD, Calder AA. Neutrophil activation in pregnancy-induced hypertension. Br J Obstet Gynaecol 1989;96:978–82.

[75] Varani J, Dame MK, Gibbs DF, Taylor CG, Weinberg JM, Shayevitz J, Ward PA. Human umbilical vein endothelial cell killing by activated neutrophils. Loss of sensitivity to injury is accompanied by decreased iron content during *in vitro* culture and is restored with exogenous iron. Lab Invest 1992;66:708–14.

[76] Baldwin RL, Tran H, Karlan BY. Primary ovarian cancer cultures are resistant to Fas-mediated apoptosis. Gynecol Oncol 1999;74:265–71.

[77] Munakata S, Enomoto T, Tsujimoto M, Otsuki Y, Miwa H, Kanno H, Aozasa K. Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms. Br J Cancer 2000;82:1446–52.

[78] Xerri L, Devilard E, Hassoun J, Mawas C, Birg F. Fas ligand is not only expressed in immune privileged human organs but is also coexpressed with Fas in various epithelial tissues. Mol Pathol 1997;50:87–91.

[79] Gutierrez L, Eliza M, Niven-Fairchild T, Naftolin F, Mor G. The Fas/Fas-ligand system: a mechanism for immune evasion in human breast carcinomas. Breast Cancer Res Treat 1999;54:245–53.

[80] Reimer T, Herrnring C, Koczan D, Richter D, Gerber B, Kabelitz D, Friese K, Thiesen HJ. FasL:Fas ratio—a prognostic factor in breast carcinomas. Cancer Res 2000;60:822–8.

[81] Das H, Koizumi T, Sugimoto T, Chakraborty S, Ichimura T, Hasegawa K, Nishimura R. Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR. Br J Cancer 2000;82:1682–8.

[82] Mottolese M, Buglioni S, Bracalenti C, Cardarelli MA, Ciabocco L, Giannarelli D, Botti C, Natali PG, Concetti A, Venanzi FM. Prognostic relevance of altered Fas (CD95)-system in human breast cancer. Int J Cancer 2000;89:127–32.

[83] Keane MM, Ettenberg SA, Lowrey GA, Russell EK, Lipkowitz S. Fas expression and function in normal and malignant breast cell lines. Cancer Res 1996;56:4791–8.

[84] Bechmann I, Mor G, Nilsen J, Eliza M, Nitsch R, Naftolin F. FasL (CD95L, Apo1L) is expressed in the normal rat and human brain: evidence for the existence of an immunological brain barrier. Glia 1999;27:62–74.

[85] Bamberger A, Schulte H, Thuneke I, Erdmann I, Bamberger C, Asa S. Expression of the apoptosis-inducing Fas ligand (FasL) in human first and third trimester placenta and choriocarcinoma cells. J Clin Endocrinol Metab 1997;82:3173–5.

[86] Mor G, Gutierrez LS, Eliza M, Kahyaoglu F, Arici A. Fas-Fas ligand system-induced apoptosis in human placenta and gestational trophoblastic disease. Am J Reprod Immunol 1998;40:89–94.

[87] O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996;184:1075–82.

[88] O'Connell J, Bennett MW, Nally K, O'Sullivan GC, Collins JK, Shanahan F. Interferon-γ sensitizes colonic epithelial cell lines to physiological and therapeutic inducers of colonocyte apoptosis. J Cell Physiol 2000;185:331–8.

[89] O'Connell J, Houston A, Bennett MW, O'Sullivan GC, Shanahan F. Immune privilege or inflammation? Insights into the Fas ligand enigma. Nat Med 2001;7:271–4.

[90] Mor G, Wei Y, Santen R, Gutierrez L, Eliza M, Lev B, Harada N, Wang J, Lysiak J, Diano S, Naftolin F. Macrophages, estrogen and the microenvironment of breast cancer. J Steroid Biochem Mol Biol 1998;67:403–11.